


Hope
Robinson

1653

BIOTECHNOLOGY
SYSTEMS
BRANCH



p#15

RAW SEQUENCE LISTING
ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/443,986B
Source: 1600 RUSH
Date Processed by STIC: 7/2/2002

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.

PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax)

PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE **CHECKER**
VERSION 3.1 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND
TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/ebc/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. Hand Carry directly to:
U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name,
Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202
Or
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two,
2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office,
Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

RECEIVED

JUL 08 2002

TECH CENTER 1600/2900



1600

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/443,986B

DATE: 07/02/2002

TIME: 10:17:32

Input Set : A:\EP.txt

Output Set: N:\CRF3\07022002\I443986B.raw

see pp 2, 4-6

**Does Not Comply
Corrected Diskette Needed**

3 <110> APPLICANT: Elan Corporation
 4 O'Mahony, Daniel J.
 6 <120> TITLE OF INVENTION: RETRO-INVERSION PEPTIDES THAT TARGET GIT TRANSPORT RECEPTORS
 AND RELATED
 7 METHODS
 9 <130> FILE REFERENCE: 99.1064.US/E1067/20019
 11 <140> CURRENT APPLICATION NUMBER: US 09/443,986B
 12 <141> CURRENT FILING DATE: 1999-11-19
 14 <160> NUMBER OF SEQ ID NOS: 85
 16 <170> SOFTWARE: PatentIn version 3.1
 18 <210> SEQ ID NO: 1
 19 <211> LENGTH: 15
 20 <212> TYPE: PRT
 OK> 21 <213> ORGANISM: Artificial
 23 <220> FEATURE:
 24 <223> OTHER INFORMATION: PAX2 15 mer fragment-D form retroinversion
 26 <400> SEQUENCE: 1
 28 Arg Thr Arg Leu Arg Arg Asn His Ser Ser His Lys Ala Asn Thr
 29 1 5 10 15
 32 <210> SEQ ID NO: 2
 33 <211> LENGTH: 16
 34 <212> TYPE: PRT
 OK> 35 <213> ORGANISM: Artificial
 37 <220> FEATURE:
 38 <223> OTHER INFORMATION: P31 16 mer fragment- D form retroinversion
 40 <400> SEQUENCE: 2
 42 Gly Pro His Arg Arg Gly Arg Pro Asn Ser Arg Ser Ser Lys Arg Thr
 43 1 5 10 15
 46 <210> SEQ ID NO: 3
 47 <211> LENGTH: 14
 48 <212> TYPE: PRT
 OK> 49 <213> ORGANISM: Artificial
 51 <220> FEATURE:
 52 <223> OTHER INFORMATION: HAX42 14 mer fragment-D form retroinversion
 54 <400> SEQUENCE: 3
 56 Gly Thr Ser Asn Gly Asn Gly Cys Cys Asn Tyr Asp Gly Pro
 57 1 5 10
 60 <210> SEQ ID NO: 4
 61 <211> LENGTH: 15
 62 <212> TYPE: PRT
 OK> 63 <213> ORGANISM: Artificial
 65 <220> FEATURE:
 66 <223> OTHER INFORMATION: PAX2 15 mer fragment
 68 <400> SEQUENCE: 4

RAW SEQUENCE LISTING

DATE: 07/02/2002

PATENT APPLICATION: US/09/443,986B

TIME: 10:17:32

Input Set : A:\EP.txt

Output Set: N:\CRF3\07022002\I443986B.raw

70 Thr Asn Ala Lys His Ser Ser His Asn Arg Arg Leu Arg Thr Arg

71 1 5 10 15

74 <210> SEQ ID NO: 5

75 <211> LENGTH: 16

76 <212> TYPE: PRT

OK> 77 <213> ORGANISM: Artificial

79 <220> FEATURE:

80 <223> OTHER INFORMATION: P31 16 mer fragment

82 <400> SEQUENCE: 5

84 Thr Arg Lys Ser Ser Arg Ser Asn Pro Arg Gly Arg Arg His Pro Gly

85 1 5 10 15

88 <210> SEQ ID NO: 6

89 <211> LENGTH: 14

90 <212> TYPE: PRT

OK> 91 <213> ORGANISM: Artificial

93 <220> FEATURE:

94 <223> OTHER INFORMATION: HAX42 14 mer fragment

96 <400> SEQUENCE: 6

98 Pro Gly Asp Tyr Asn Cys Cys Gly Asn Gly Asn Ser Thr Gly

99 1 5 10

102 <210> SEQ ID NO: 7

103 <211> LENGTH: 40

104 <212> TYPE: PRT

OK> 105 <213> ORGANISM: Artificial

107 <220> FEATURE:

108 <223> OTHER INFORMATION: PAX2 full length

110 <400> SEQUENCE: 7

112 Ser Thr Pro Pro Ser Arg Glu Ala Tyr Ser Arg Pro Tyr Ser Val Asp

113 1 5 10 15

116 Ser Asp Ser Asp Thr Asn Ala Lys His Ser Ser His Asn Arg Arg Leu

117 20 25 30

120 Arg Thr Arg Ser Arg Pro Asn Gly

121 35 40

124 <210> SEQ ID NO: 8

125 <211> LENGTH: 44

126 <212> TYPE: PRT

C--> 127 <213> ORGANISM: Artificial

129 <220> FEATURE:

130 <223> OTHER INFORMATION: HAX42 full length with additional L-Lysine

132 <220> FEATURE:

133 <221> NAME/KEY: MOD_RES

134 <222> LOCATION: (1)..(1)

135 <223> OTHER INFORMATION: Dansylated L-Lysine

138 <400> SEQUENCE: 8

140 Ser Asp His Ala Leu Gly Thr Asn Leu Arg Ser Asp Asn Ala Lys Glu

141 1 5 10 15

144 Pro Gly Asp Tyr Asn Cys Cys Gly Asn Gly Asn Ser Thr Gly Arg Lys

145 20 25 30

148 Val Phe Asn Arg Arg Arg Pro Ser Ala Ile Pro Thr

"Ser" is at location 1

RAW SEQUENCE LISTING

DATE: 07/02/2002

PATENT APPLICATION: US/09/443,986B

TIME: 10:17:32

Input Set : A:\EP.txt

Output Set: N:\CRF3\07022002\I443986B.raw

```

149          35          40
152 <210> SEQ ID NO: 9
153 <211> LENGTH: 16
154 <212> TYPE: PRT
155 <213> ORGANISM: Artificial
157 <220> FEATURE:
158 <223> OTHER INFORMATION: ZElan 144; PAX2 15 mer fragment-D form retroinversion with
addi
159          tional L-lysine in position 1
161 <220> FEATURE:
162 <221> NAME/KEY: MOD_RES
163 <222> LOCATION: (1)..(1)
164 <223> OTHER INFORMATION: Dansylated L-lysine
167 <400> SEQUENCE: 9
169 Lys Arg Thr Arg Leu Arg Arg Asn His Ser Ser His Lys Ala Asn Thr
170 1          5          10          15
173 <210> SEQ ID NO: 10
174 <211> LENGTH: 17
175 <212> TYPE: PRT
176 <213> ORGANISM: Artificial
178 <220> FEATURE:
179 <223> OTHER INFORMATION: ZElan 145; P31 16 mer fragment- D form retroinversion with
additi
180          onal L-lysine in position 1
182 <220> FEATURE:
183 <221> NAME/KEY: MOD_RES
184 <222> LOCATION: (1)..(1)
185 <223> OTHER INFORMATION: dansylated L-lysine
188 <400> SEQUENCE: 10
190 Lys Gly Pro His Arg Arg Gly Arg Pro Asn Ser Arg Ser Ser Lys Arg
191 1          5          10          15
194 Thr
198 <210> SEQ ID NO: 11
199 <211> LENGTH: 15
200 <212> TYPE: PRT
201 <213> ORGANISM: Artificial
203 <220> FEATURE:
204 <223> OTHER INFORMATION: ZElan 146; HAX42 14 mer fragment-D form retroinversion with
addit
205          ional L-Lysine in position 1
207 <220> FEATURE:
208 <221> NAME/KEY: MOD_RES
209 <222> LOCATION: (1)..(1)
210 <223> OTHER INFORMATION: dansylated L-Lysine
213 <400> SEQUENCE: 11
215 Lys Gly Thr Ser Asn Gly Asn Gly Cys Cys Asn Tyr Asp Gly Pro
216 1          5          10          15
219 <210> SEQ ID NO: 12
220 <211> LENGTH: 16
221 <212> TYPE: PRT
222 <213> ORGANISM: Artificial
224 <220> FEATURE:

```

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/443,986B

DATE: 07/02/2002
TIME: 10:17:32

Input Set : A:\EP.txt
Output Set: N:\CRF3\07022002\I443986B.raw

225 <223> OTHER INFORMATION: ZElan 129; PAX2 15 mer fragment with additional L-Lysine in
posi
226 tion 1
228 <220> FEATURE:
229 <221> NAME/KEY: MOD_RES
230 <222> LOCATION: (1)..(1)
231 <223> OTHER INFORMATION: dansylated L-Lysine
234 <400> SEQUENCE: 12
236 Lys Thr Asn Ala Lys His Ser Ser His Asn Arg Arg Leu Arg Thr Arg
237 1 5 10 15
240 <210> SEQ ID NO: 13
241 <211> LENGTH: 17
242 <212> TYPE: PRT
Q- 243 <213> ORGANISM: Artificial
245 <220> FEATURE:
246 <223> OTHER INFORMATION: ZElan 031; P31 16 mer fragment with additional L-Lysine in
positi
247 on 1
249 <220> FEATURE:
250 <221> NAME/KEY: MOD_RES
251 <222> LOCATION: (1)..(1)
252 <223> OTHER INFORMATION: dansylated L-Lysine
255 <400> SEQUENCE: 13
257 Lys Thr Arg Lys Ser Ser Arg Ser Asn Pro Arg Gly Arg Arg His Pro
258 1 5 10 15
261 Gly
265 <210> SEQ ID NO: 14
266 <211> LENGTH: 15
267 <212> TYPE: PRT
Q- 268 <213> ORGANISM: Artificial
270 <220> FEATURE:
271 <223> OTHER INFORMATION: ZElan 091; HAX42 14 mer fragment with additional L-lysine in
posi
272 tion 1
274 <220> FEATURE:
275 <221> NAME/KEY: MOD_RES
276 <222> LOCATION: (1)..(1)
277 <223> OTHER INFORMATION: dansylated L-lysine
280 <400> SEQUENCE: 14
282 Lys Pro Gly Asp Tyr Asn Cys Cys Gly Asn Gly Asn Ser Thr Gly
283 1 5 10 15
286 <210> SEQ ID NO: 15
287 <211> LENGTH: 40
288 <212> TYPE: PRT
Q- 289 <213> ORGANISM: Artificial
291 <220> FEATURE:
292 <223> OTHER INFORMATION: PAX2 full length with additional L-lysine in position 1
294 <220> FEATURE:
295 <221> NAME/KEY: MOD_RES
296 <222> LOCATION: (1)..(1)
297 <223> OTHER INFORMATION: dansylated L-Lysine
300 <400> SEQUENCE: 15

Ser is at location 1

see p.5

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/443,986B

DATE: 07/02/2002

TIME: 10:17:32

Input Set : A:\EP.txt

Output Set : N:\CRF3\07022002\I443986B.raw

301 Ser Thr Pro Pro Ser Arg Glu Ala Tyr Ser Arg Pro Tyr Ser Val Asp
 303 1 5 10 15
 306 Ser Asp Ser Asp Thr Asn Ala Lys His Ser Ser His Asn Arg Arg Leu
 307 20 25 30
 310 Arg Thr Arg Ser Arg Pro Asn Gly
 311 35 40

314 <210> SEQ ID NO: 16

315 <211> LENGTH: 44

316 <212> TYPE: PRT

317 <213> ORGANISM: Artificial

319 <220> FEATURE:

320 <223> OTHER INFORMATION: S15 44 mer fragment L-form

322 <400> SEQUENCE: 16

324 Arg Ser Gly Ala Tyr Glu Ser Pro Asp Gly Arg Gly Gly Arg Ser Tyr

325 1 5 10 15

328 Val Gly Gly Gly Gly Gly Cys Gly Asn Ile Gly Arg Lys His Asn Leu

329 20 25 30

332 Trp Gly Leu Arg Thr Ala Ser Pro Ala Cys Trp Asp

333 35 40

336 <210> SEQ ID NO: 17

337 <211> LENGTH: 44

338 <212> TYPE: PRT

339 <213> ORGANISM: Artificial

341 <220> FEATURE:

342 <223> OTHER INFORMATION: S21 44 mer fragment L-form

344 <400> SEQUENCE: 17

346 Ser Pro Arg Ser Phe Trp Pro Val Val Ser Arg His Glu Ser Phe Gly

347 1 5 10 15

350 Ile Ser Asn Tyr Leu Gly Cys Gly Tyr Arg Thr Cys Ile Ser Gly Thr

351 20 25 30

354 Met Thr Lys Ser Ser Pro Ile Tyr Pro Arg His Ser

355 35 40

358 <210> SEQ ID NO: 18

359 <211> LENGTH: 44

360 <212> TYPE: PRT

361 <213> ORGANISM: Artificial

363 <220> FEATURE:

364 <223> OTHER INFORMATION: S22 44 mer fragment L-form

366 <400> SEQUENCE: 18

368 Ser Ser Ser Ser Asp Trp Gly Gly Val Pro Gly Lys Val Val Arg Glu

369 1 5 10 15

372 Arg Phe Lys Gly Arg Gly Cys Gly Ile Ser Ile Thr Ser Val Leu Thr

373 20 25 30

376 Gly Lys Pro Asn Pro Cys Pro Glu Pro Lys Ala Ala

377 35 40

380 <210> SEQ ID NO: 19

381 <211> LENGTH: 44

382 <212> TYPE: PRT

383 <213> ORGANISM: Artificial

RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION: US/09/443,986B

DATE: 07/02/2002
TIME: 10:17:33

Input Set : A:\EP.txt
Output Set: N:\CRF3\07022002\I443986B.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:73; Xaa Pos. 1,3,4,6,7,8,10

Seq#:74; Xaa Pos. 2,4,7,8

Seq#:75; Xaa Pos. 7,8

Invalid Line Length:

The rules require that a line not exceed 72 characters in length. This includes spaces.

Seq#:1; Line(s) 6

Invalid <213> Response:

Use of "Artificial" only as "<213> Organism" response is incomplete, per 1.823(b) of New Sequence Rules. Valid response is Artificial Sequence.

Seq#:1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27

Seq#:28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51

Seq#:52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75

Seq#:76,77,78,79,80,81,82,83,84,85

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.

☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).

☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).

☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."

☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).

☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).

☐ 7. Other: the specification and the claims do not have sequence identification numbers at each sequence as required by 37 CFR 1.821(d).

Applicant Must Provide:

☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE